InMed Pharmaceuticals Stock Forecast, Price & News

InMed Pharmaceuticals (NASDAQ:INM) Frequently Asked Questions

Is InMed Pharmaceuticals a buy right now?

1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for InMed Pharmaceuticals in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" InMed Pharmaceuticals stock.
View analyst ratings for InMed Pharmaceuticals or view top-rated stocks.

What stocks does MarketBeat like better than InMed Pharmaceuticals?

Wall Street analysts have given InMed Pharmaceuticals a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but InMed Pharmaceuticals wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting InMed Pharmaceuticals?

InMed Pharmaceuticals saw a increase in short interest during the month of September. As of September 30th, there was short interest totaling 66,800 shares, an increase of 189.2% from the September 15th total of 23,100 shares. Based on an average trading volume of 206,900 shares, the short-interest ratio is presently 0.3 days. Approximately 0.8% of the shares of the company are short sold.
View InMed Pharmaceuticals' Short Interest.

When is InMed Pharmaceuticals' next earnings date?

InMed Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Thursday, December 16th 2021.
View our earnings forecast for InMed Pharmaceuticals.

How were InMed Pharmaceuticals' earnings last quarter?

InMed Pharmaceuticals Inc. (NASDAQ:INM) issued its quarterly earnings data on Thursday, September, 23rd. The company reported ($0.41) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.34) by $0.07.
View InMed Pharmaceuticals' earnings history.

What price target have analysts set for INM?

1 brokerages have issued 1-year price objectives for InMed Pharmaceuticals' stock. Their forecasts range from $11.50 to $11.50. On average, they expect InMed Pharmaceuticals' share price to reach $11.50 in the next twelve months. This suggests a possible upside of 666.7% from the stock's current price.
View analysts' price targets for InMed Pharmaceuticals or view top-rated stocks among Wall Street analysts.

Who are InMed Pharmaceuticals' key executives?

InMed Pharmaceuticals' management team includes the following people:

• Mr. Eric A. Adams, Pres, CEO & Director (Age 57, Pay $423.76k)
• Mr. Bruce S. Colwill C.A., CPA, CA, CFO & Corp. Sec. (Age 56, Pay $313.13k)
• Ms. Alexandra Diane-Janet Mancini, Sr. VP of Clinical & Regulatory Affairs (Age 68, Pay $308.19k)
• Dr. Eric Chih-Hsien Hsu, Sr. VP of Preclinical R&D (Age 51, Pay $248.99k)
• Mr. Michael Woudenberg P.Eng., VP of Chemistry, Manufacturing & Controls (Age 54, Pay $238.14k)
• Dr. Sazzad Hossain, Co-Founder
• Mr. Brendan Payne, Director of Investor Relations
• Mr. Richard Hoy, VP of Sales & Marketing
• Dr. Ado Muhammad, Sr. Consultant of Medical Affairs

Who are some of InMed Pharmaceuticals' key competitors?

Some companies that are related to InMed Pharmaceuticals include Rezolute (RZLT), Rezolute (RZLTD), Acurx Pharmaceuticals (ACXP), Liminal BioSciences (LMNL), Ensysce Biosciences (ENSC), Cellectar Biosciences (CLRB), Newron Pharmaceuticals (NWPHF), Rockwell Medical (RMTI), Acerus Pharmaceuticals (ASPCF), FSD Pharma (HUGE), Virpax Pharmaceuticals (VRPX), Reviva Pharmaceuticals (RVPH), Assertio (ASRT), Diffusion Pharmaceuticals (DFFN) and CURE Pharmaceutical (CURR).
View all of INM's competitors.

What is InMed Pharmaceuticals' stock symbol?

InMed Pharmaceuticals trades on the NASDAQ under the ticker symbol "INM."

How do I buy shares of InMed Pharmaceuticals?

Shares of INM can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is InMed Pharmaceuticals' stock price today?

One share of INM stock can currently be purchased for approximately $1.50.

How much money does InMed Pharmaceuticals make?

InMed Pharmaceuticals has a market capitalization of $14.07 million. The company earns $-10.20 million in net income (profit) each year or ($1.52) on an earnings per share basis.

How many employees does InMed Pharmaceuticals have?

InMed Pharmaceuticals employs 20 workers across the globe.

What is InMed Pharmaceuticals' official website?

The official website for InMed Pharmaceuticals is www.inmedpharma.com.

How can I contact InMed Pharmaceuticals?

The company can be reached via phone at 604-669-7207 or via email at [email protected].